To understand the future of these preclinical studies, we sat down with James Keck, Ph.D., who was recently recognized as a JAX President’s Innovation Fellow for his work creating mouse-based platforms to study the immune system, and evaluate new therapeutics for both safety and efficacy.
The Jackson Laboratory has hired its 125th employee at the Charles E. Hewett Center in Ellsworth. The Center opened just three years ago to enable wider access to vital JAX mouse resources for the worldwide biomedical research community.
Mice with different genetic backgrounds exhibit highly variable responses to SARS-CoV-2 infection, mirroring the large differences in COVID-19 disease severity seen in humans.
JAX Associate Professor Greg Cox discovered that mutations in NEMF, a key component of RQC, cause neuromuscular disorders in mice. He also identified human patients with pathogenic variants in NEMF who exhibit both motor neuron dysfunction and intellectual disabilities, underscoring RQC’s clinical importance.